Healthcare
Live Price
Offline$101.25
+0.00% today
1Y Change
+1290.80%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abivax S.A. (AAVXF) is a Healthcare stock with a market cap of $7.94B and listed on OTC. The stock last traded around $101.25 and up 1290.8% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -72.5%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -72.5%, free cash flow -4.8% with operating margin 0.0% and ROIC -48.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AAVXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AAVXF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AAVXF Max Drawdown
-46.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AAVXF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$37.0K
-99.2% YoY
FY Net Income
-$41.4M
+40.8% YoY
Free Cash Flow
-$47.3M
+32.0% YoY
Revenue Growth
-100.0%
EPS Growth
-72.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 11M | 5M | 5M | 37K |
| Gross Profit | -1M | 11M | 4M | 5M | -119K |
| Operating Income | -251M | -173M | -127M | -57M | -52M |
| EBITDA | -249M | -172M | -133M | -53M | -39M |
| Net Income | -336M | -176M | -148M | -70M | -41M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 516M | 144M | 252M | 27M | 61M |
| Total Assets | 584M | 205M | 327M | 73M | 110M |
| Total Liabilities | 129M | 165M | 131M | 71M | 82M |
| Shareholder Equity | 455M | 41M | 196M | 2M | 29M |
| Total Debt | 32M | 97M | 59M | 47M | 53M |
| Net Debt | -484M | -47M | -193M | 20M | -7M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
46M
+30.4% YoY
Capital Expenditures
2M
+58.6% YoY
Free Cash Flow
47M
+32.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-165.2%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.